Authors : Joseph Kobi; Millicent Naa Oye Boadu; Dorothy Honny Bendah; Bernard Afoakwah; Dr. Brian Otieno Odhiambo

Volume/Issue : Volume 10 - 2025, Issue 2 - February

Google Scholar : https://tinyurl.com/3beta3uu

Scribd : https://tinyurl.com/yc4mpk34

DOI : https://doi.org/10.5281/zenodo.14937080

Abstract : Introduction: The treatment response patterns for breast cancer exhibit substantial variations between different ethnic groups among the America's population. Research examining whole populations shows major variations exist between racial and ethnic groups regarding their incidence rates as well as death rates and survival possibilities. Statistical modeling represents an essential framework to study treatment patterns and forecast treatment results. Current epidemiological research documents a steady 0.5% growth of breast cancer incident cases within hormone receptor-positive localized-stage diseases but shows decreasing death statistics from 1989 onward.  Materials and Methods: A wide-ranging breast cancer data study utilized multiple statistical modeling procedures for its assessment. The distribution among populations became clear by analyzing breast cancer subtype patterns with immunohistochemistry tests which identified the presence of luminal A, luminal B, basal-like, and HER2+/ER- cancer types. A combination of complex statistical methods analyzed treatment response patterns including tumor traits and molecular subtype information together with patient demographics and clinical data results.  Results: The analysis found Black women experienced increased deaths by 40% than White women even though their breast cancer incidence levels remained at 127.8 per 100,000 below White women's 133.7 rate. Detailed numbers show that Basal- like breast cancer affected 39% of premenopausal African American women yet only 14% of postmenopausal African American women and 16% of non-African American women experienced this cancer type. The survival outcomes for Black and White populations differed by 8% for those with hormone receptor-positive/HER2-negative disease (88% survival for Blacks compared to 96% for Whites).  Discussion: The systematic analysis through predictive modeling uncovered separate response patterns in treatments when evaluating different ethnic groups while showing the varying healthcare availability and affects. Statistics revealed the molecular subtypes' survival durations differed noticeably as HER2+/ER- and basal-like examples had the most rapid disease progression. Analysis revealed prolonged treatments weren't equitable for younger Black females below 50 due to biological and socioeconomic influences which accumulated persistently across groups.  Conclusion: Statistical modeling approaches deliver important findings concerning the treatment response pathways that ethnic groups experience after breast cancer diagnosis. The modeling results demonstrate persistent ethnic inequalities together with different therapeutic results by molecular subtype therefore requiring targeted healthcare system reforms. Statistical modeling of these patterns will enhance understanding for creating personalized treatment strategies which in turn improves outcomes for every demographic group.

Keywords : Breast Cancer, Statistical Models, Ethnic Populations, Treatment Response, Racial Disparities, Molecular Subtypes, Prognosis Indicators, Mammography Screening, Hormone Receptor Status.

References :

1. American Cancer Society (ACS) (2022) Cancer facts & figures 2022. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf.
2. Polyak, K. (2007). Breast cancer: origins and evolution. The Journal of clinical investigation, 117(11), 3155-3163. https://www.jci.org/117/11/3155?content_type=short&rss=1
3. Habel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., ... & Quesenberry, C. P. (2006). A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Research, 8, 1-15.
4. Yedjou, C. G., Tchounwou, P. B., Payton, M., Miele, L., Fonseca, D. D., Lowe, L., & Alo, R. A. (2017). Assessing the racial and ethnic disparities in breast cancer mortality in the United States. International journal of environmental research and public health, 14(5), 486. https://www.mdpi.com/1660-4601/14/5/486
5. Guerrero, S., López-Cortés, A., Indacochea, A., García-Cárdenas, J. M., Zambrano, A. K., Cabrera-Andrade, A., ... & Paz-y-Miño, C. (2018). Analysis of racial/ethnic representation in select basic and applied cancer research studies. Scientific reports, 8(1), 13978. https://www.nature.com/articles/s41598-018-32264-x
6. Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. Journal of clinical oncology, 23(29), 7350-7360. https://ascopubs.org/doi/abs/10.1200/jco.2005.03.3845
7. Vernon, S. W., Tilley, B. C., Neale, A. V., & Steinfeldt, L. (1985). Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer, 55(7), 1563-1571. https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19850401)55:7%3C1563::AID-CNCR2820550726%3E3.0.CO;2-1
8. Donovan, K. A., Small, B. J., Andrykowski, M. A., Munster, P., & Jacobsen, P. B. (2007). Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. Health Psychology, 26(4), 464. https://psycnet.apa.org/record/2007-09406-010
9. Delen, D., Walker, G., & Kadam, A. (2005). Predicting breast cancer survivability: a comparison of three data mining methods. Artificial intelligence in medicine, 34(2), 113-127. https://www.sciencedirect.com/science/article/pii/S0933365704001010
10. Peppercorn, J., Perou, C. M., & Carey, L. A. (2007). Molecular subtypes in breast cancer evaluation and management: divide and conquer. Breast Cancer, 125-142. https://www.taylorfrancis.com/chapters/edit/10.3109/9781420019940-14/molecular-subtypes-breast-cancer-evaluation-management-divide-conquer-jeffrey-peppercorn-charles-perou-lisa-carey
11. Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Elledge, R., ... & O'Connell, P. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet, 362(9381), 362-369.
12. Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L. E., Petrovic, I., Lai, Q., ... & Lewis, M. T. (2013). A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer research, 73(15), 4885-4897. https://aacrjournals.org/cancerres/article-abstract/73/15/4885/584224
13. Shavers, V. L., & Brown, M. L. (2002). Racial and ethnic disparities in the receipt of cancer treatment. Journal of the National Cancer Institute, 94(5), 334-357.  https://academic.oup.com/jnci/article-abstract/94/5/334/2520084
14. Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association, 20(6), 1059-1066. https://academic.oup.com/jamia/article-abstract/20/6/1059/702678
15. Børresen‐Dale, A. L. (2003). TP53 and breast cancer. Human mutation, 21(3), 292-300. https://onlinelibrary.wiley.com/doi/abs/10.1002/humu.10174
16. Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., ... & Pusztai, L. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical cancer research, 11(16), 5678-5685. https://aacrjournals.org/clincancerres/article-abstract/11/16/5678/185584
17. Fackenthal, J. D., & Olopade, O. I. (2007). Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nature Rev
18. Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., ... & Siegel, R. L. (2022). Breast cancer statistics, 2022. CA: a cancer journal for clinicians, 72(6), 524-541. https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21754
19. Kurian, A. W., Fish, K., Shema, S. J., & Clarke, C. A. (2010). Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Research, 12, 1-9. https://link.springer.com/article/10.1186/bcr2780
20. Tice, J. A., Cummings, S. R., Smith-Bindman, R., Ichikawa, L., Barlow, W. E., & Kerlikowske, K. (2008). Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Annals of internal medicine, 148(5), 337-347. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-148-5-200803040-00004
21. Nattinger, A. B., Gottlieb, M. S., Veum, J., Yahnke, D., & Goodwin, J. S. (1992). Geographic variation in the use of breast-conserving treatment for breast cancer. New England Journal of Medicine, 326(17), 1102-1107. https://www.nejm.org/doi/abs/10.1056/NEJM199204233261702
22. Hawley, S. T., Griggs, J. J., Hamilton, A. S., Graff, J. J., Janz, N. K., Morrow, M., ... & Katz, S. J. (2009). Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. Journal of the National Cancer Institute, 101(19), 1337-1347.  https://academic.oup.com/jnci/article-abstract/101/19/1337/1073312
23. Conti, A., Duggento, A., Indovina, I., Guerrisi, M., & Toschi, N. (2021, July). Radiomics in breast cancer classification and prediction. In Seminars in cancer biology (Vol. 72, pp. 238-250). Academic Press. https://www.sciencedirect.com/science/article/pii/S1044579X20300833
24. Wang, Y., Yin, Q., Yu, Q., Zhang, J., Liu, Z., Wang, S., ... & Niu, Y. (2011). A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast cancer research and treatment, 130, 489-498. https://link.springer.com/article/10.1007/s10549-011-1709-6
25. Barlow, W. E., White, E., Ballard-Barbash, R., Vacek, P. M., Titus-Ernstoff, L., Carney, P. A., ... & Kerlikowske, K. (2006). Prospective breast cancer risk prediction model for women undergoing screening mammography. Journal of the National Cancer Institute, 98(17), 1204-1214. https://academic.oup.com/jnci/article-abstract/98/17/1204/2521747
26. Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., ... & Belay, A. (2022). [Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed research international, 2022(1), 9605439. https://onlinelibrary.wiley.com/doi/abs/10.1155/2022/9605439
27. Lee, M. M., Lin, S. S., Wrensch, M. R., Adler, S. R., & Eisenberg, D. (2000). Alternative therapies used by women with breast cancer in four ethnic populations. Journal of the National Cancer Institute, 92(1), 42-47. https://academic.oup.com/jnci/article-abstract/92/1/42/2905777
28. Cronin, M., Sangli, C., Liu, M. L., Pho, M., DuTTA, D., NGuYEN, A., ... & Watson, D. (2007). Analytical Validation of the Onco type DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer. Clinical chemistry, 53(6), 1084-1091. https://academic.oup.com/clinchem/article-abstract/53/6/1084/5627574
29. Brown, M., Tsodikov, A., Bauer, K. R., Parise, C. A., & Caggiano, V. (2008). The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004. Cancer, 112(4), 737-747. https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.23243
30. O'Brien, K. M., Cole, S. R., Tse, C. K., Perou, C. M., Carey, L. A., Foulkes, W. D., ... & Millikan, R. C. (2010). Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical Cancer Research, 16(24), 6100-6110. https://aacrjournals.org/clincancerres/article-abstract/16/24/6100/75628
31. Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., ... & Goldhirsch, A. (2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clinical Cancer Research, 10(19), 6622-6628.
32. Wang, H., Zhang, C., Zhang, J., Kong, L., Zhu, H., & Yu, J. (2016). The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. Oncotarget, 8(16), 26368.
33. Elledge, R. M., Clark, G. M., Chamness, G. C., & Osborne, C. K. (1994). Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. JNCI: Journal of the National Cancer Institute, 86(9), 705-712. https://academic.oup.com/jnci/article-abstract/86/9/705/922405
34. Bellizzi, K. M., & Blank, T. O. (2006). Predicting posttraumatic growth in breast cancer survivors. Health Psychology, 25(1), 47. https://psycnet.apa.org/journals/hea/25/1/47/
35. Dressman, H. K., Hans, C., Bild, A., Olson, J. A., Rosen, E., Marcom, P. K., ... & Blackwell, K. (2006). Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clinical Cancer Research, 12(3), 819-826. https://aacrjournals.org/clincancerres/article-abstract/12/3/819/194225
36. Listgarten, J., Damaraju, S., Poulin, B., Cook, L., Dufour, J., Driga, A., ... & Zanke, B. (2004). Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clinical cancer research, 10(8), 2725-2737. https://aacrjournals.org/clincancerres/article-abstract/10/8/2725/185229